Medtech PIPE Volume, Share Gains Indicate Rebound In Private Investments
Executive Summary
A new analysis of medtech PIPE deals in Informa’s Strategic Transactions and PlacementTracker shows a rebound in transaction and dollar volume.
You may also be interested in...
Late-Stage Venture Continues To Dominate Medtech Financing
Device start-ups raised $1.7 billion in 2013, and approximately 75% of the total was from Series C or later rounds, a sign that investors are still more comfortable making investments in more advanced companies.
Giving Device PIPEs A Good Twist
According to Elsevier's Strategic Transactions, venture capital firms participated in 11 private investments in public entities in the two years prior to the economic collapse versus making 12 PIPEs in the two years that followed. Although it's too early to judge, hesitation may be warranted. Venture investors saw gains in only seven of the 12 deals.
Investors Go Berserk For Viking, Putting It Top Of Q1 Winners
The top 10 biggest share price winners and losers in Q1 from Evaluate show the investor frenzy for obesity drugs continues, while companies with governance doubts see shareholders retreat.